Hikma Pharmaceuticals Plc Non Regulatory Announcement

TIDMHIK

Hikma Pharmaceuticals Plc

03 January 2013

PRESS RELEASE

Hikma to present at the 31(st) Annual J.P. Morgan Healthcare Conference

London, 3 January 2013 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) ("Hikma"), the fast growing multinational pharmaceutical group, today announces that Mazen Darwazah, Executive Vice Chairman and CEO of MENA, will present at the 31(st) Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 in San Francisco.

The presentation is scheduled to begin at 14.30 Pacific Time, 17.30 Eastern Time and 22.30 GMT. The slides accompanying the presentation will be available on the Hikma website at www.hikma.com.

----- ENDS -----

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760/ 07776 477 050

Lucinda Henderson, Investor Relations Manager +44 (0)20 7399 2765/ 07818 060 211

FTI Consulting +44 (0)20 7831 3113

Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenues of $918.0 million and profit attributable to shareholders of $80.1 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADMGGMKFNGFZM

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024